Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Trial Profile

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABI-H0731 (Primary) ; Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 11 Nov 2019 Results presented in an Assembly Biosciences Media Release.
    • 11 Nov 2019 According to an Assembly Biosciences media release, data were presented at AASLD 2019.
    • 07 Nov 2019 According to an Assembly Biosciences media release, the company is planning to present data from this trial at the upcoming American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top